TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Time-differentiated Treatment With Mild Therapeutic Hypothermia Following Cardiac Arrest, a Multi Center Study.
Brief Summary: The purpose of this study is to determine if 48 hours of mild therapeutic hypothermia following out of hospital cardiac arrest gives a better cerebral outcome compared to 24 hours therapeutic hypothermia.


Options:
A: Inclusion Criteria:

1. Out of hospital cardiac arrest of suspected cardiac origin
2. Return of spontaneous circulation (ROSC)
3. Glasgow Coma Score \< 8
4. Estimated time interval from cardiac arrest to ROSC ≤ 60 min

Exclusion Criteria:

1. OOH-CA of suspected origin other than cardiac
2. In hospital Cardiac arrest
3. Terminal disease
4. Coagulation disorders
5. Unwitnessed asystolia
6. Time from cardiac arrest to start of hypothermia treatment \> 240 min
7. GCS ≥ 8
8. Pregnancy
9. Persistent cardiogenic shock (Systolic blood pressure \< 80 mmHg despite inotropic treatment and aortic balloon pump).
10. CPC 3-4 before cardiac arrest
11. Acute intra cerebral bleeding
12. Acute stroke
13. Acute coronary artery bypass grafting
B: Inclusion Criteria:

* in-hospital cardiac arrest
* restoration of spontanous circulation
* unconsciousness
* age over 18
* initiation of mild therapeutic hypothermia is possible within 4h after resuscitation

Exclusion Criteria:

* active bleeding
* suspicion of intra cranial bleeding
* severe infection
* aquired immun deficency
* severe rhythm disorders
* suspicion of cerebral insult
* known severe cognotive deficit before the index event
* pregnancy
* pre existing disease which makes 6 months survival unlikely
C: Inclusion Criteria:

* successful resuscitation from out-of-hospital cardiac arrest by paramedics, defined by having a palpable pulse

Exclusion Criteria:

* traumatic cause for cardiac arrest
D: Inclusion Criteria:

* Out-of-hospital cardiac arrest
* Presumed cardiac cause of cardiac arrest
* Unconscious with a FOUR-score \<M4 (not obeying verbal commands)
* Stable return of spontaneous circulation (20 min)
* Eligible for intensive care treatment without restrictions
* Inclusion within 180 minutes of ROSC

Exclusion Criteria:

* Unwitnessed cardiac arrest with an initial rhythm of asystole
* Temperature on admission \<30°C.
* On ECMO prior to ROSC
* Obvious or suspected pregnancy
* Intracranial bleeding
* On ECMO prior to ROSC
* Severe chronic obstructive pulmonary disorder (COPD) with long-term home oxygen therapy

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy (and Not Only) After Thyroid Surgery. A Randomized Double-blind Placebo-controlled Trial.
Brief Summary: Recurrent laryngeal nerve dysfunction and hypoparathyroidism are well-recognized important complications of thyroid surgery. The duration of convalescence, after non complicated thyroid operation, may depend on several factors of which pain and fatigue are the most important. Nausea and vomiting occur mainly on the day of operation. Glucocorticoids are well known for their analgesic, anti-inflammatory, immune modulating and antiemetic effects. The investigators therefore undertook the present study to investigate whether preoperative dexamethasone could improve surgical outcome in patients undergoing thyroid surgery.


Options:
A: Inclusion Criteria:

* female gender, non-smoking and use of postoperative opioids undergoing laparocopic abdominal surgery

Exclusion criteria included laparoscopic abdominal surgey, allergy to one of the study drugs, opioid dependence, history of gastro-intestinal disease or Parkinson's disease, history of previous PONV and motion sickness, contra-indication for epidural block (previous back surgery, bleeding diathesis or neurological dysfunction), anti-emetic medication within 24 h before surgery, inability to use the PCEA device or comprehend the visual analogue scales (VAS) for pain and nausea assessment, or unwillingness to be enrolled in the study.
B: Inclusion Criteria:

* Patients undergoing lumbar disc surgery in general anaesthesia.
* Patients who have given their written consent to participate and understand the contents of the protocol.
* ASA 1-3.
* BMI \> 18 og \< 40.
* Fertile women need a negative HCG urine test.

Exclusion Criteria:

* Patients who cannot cooperate to the study.
* Patients who do not speak and/or understand Danish.
* Fertile women with a positive HCG urine test.
* Allergy to the drugs used in the trial.
* Alcohol or medicine abuse, assessed by investigator.
* Patients who have had spine surgery before.
* Daily use of strong opioids (morphine, ketobemidone, oxynorm, methadone, fentanyl)
* Daily oral steroid treatment.
C: Inclusion Criteria:

* Age: 18\< or =, = or \<70 with benign gynecologic disease
* ASA-Class I-II
* No-definite malignancy by US, CT/MRI, CA 125 \< 500IU/ml
* Non-smoker

Exclusion Criteria:

* Conversion to laparotomy
* Hx of malignancy
* Smoker
* Suspicious malignancy
D: Inclusion Criteria:

* patients undergoing thyroid surgery

Exclusion Criteria:

* ASA physical class III or IV
* age \> 75 years
* pregnancy

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy (and Not Only) After Thyroid Surgery. A Randomized Double-blind Placebo-controlled Trial.
Brief Summary: Recurrent laryngeal nerve dysfunction and hypoparathyroidism are well-recognized important complications of thyroid surgery. The duration of convalescence, after non complicated thyroid operation, may depend on several factors of which pain and fatigue are the most important. Nausea and vomiting occur mainly on the day of operation. Glucocorticoids are well known for their analgesic, anti-inflammatory, immune modulating and antiemetic effects. The investigators therefore undertook the present study to investigate whether preoperative dexamethasone could improve surgical outcome in patients undergoing thyroid surgery.


Options:
A: Inclusion Criteria:

* Arthroscopic subacromial decompression and/or acromioclavicular resection
* General anaesthesia
* Daysurgery, Horsens Hospital

Exclusion Criteria:

* Incompetent
* Pregnant
* Age under 18 or over 90 years
* Allergy toward dexamethasone
* Diabetes
* Active gastric ulcer
* Untreated hypertension
* Glaucoma
* Daily use of glucocorticoids or strong opioids
* Daily use of analgesics for unrelated illness
* Myasthenia gravis
* Mitochondrial disorders
B: Inclusion Criteria:

* Scheduled for a diagnostic laparoscopy for suspected appendicitis
* ASA clas I-III

Exclusion Criteria:

* Known inflammatory bowel disease
* Known autoimmune disease.
* Chronic pain patient.
* Pregnant or breastfeeding.
* In treatment with systemic corticoid steroids or immune-depressants.
* Known glaucoma.
* Known ocular herpes simplex.
* Vaccination within 14 days prior to inclusion.
* Known cushing's disease.
* Known myasthenia gravis.
* Presumably poor compliance with study protocol.
C: Inclusion Criteria:

* patients undergoing thyroid surgery

Exclusion Criteria:

* ASA physical class III or IV
* age \> 75 years
* pregnancy
D: Inclusion Criteria:

* Colon resection expected to last \>2 and \<6 hours

Exclusion Criteria:

* Bowel obstruction
* Fever

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy (and Not Only) After Thyroid Surgery. A Randomized Double-blind Placebo-controlled Trial.
Brief Summary: Recurrent laryngeal nerve dysfunction and hypoparathyroidism are well-recognized important complications of thyroid surgery. The duration of convalescence, after non complicated thyroid operation, may depend on several factors of which pain and fatigue are the most important. Nausea and vomiting occur mainly on the day of operation. Glucocorticoids are well known for their analgesic, anti-inflammatory, immune modulating and antiemetic effects. The investigators therefore undertook the present study to investigate whether preoperative dexamethasone could improve surgical outcome in patients undergoing thyroid surgery.


Options:
A: Inclusion Criteria:

* patients planned for elective laparoscopic hernia repair (TAPP)
* Unilateral inguinal or femoral hernia
* ASA class I-II
* Read and speak Danish

Exclusion Criteria:

* Acute hernia operation
* Operation for other hernias with mesh during the same procedure
* Endocrine disease (diabetes, adrenal insufficiency etc.)
* fever/infection within the first 10 days before operation
* Poor compliance
* No signed consent form
* Daily intake of opioids or anxiolytic drugs
* Manic episodes
* Use medicine against glaucoma
* Use thiazide or loop diuretics
* Vaccination within the last 14 days
B: Inclusion Criteria:

* age\>18
* any cardiac procedure with sternotomy
* able to give informed consent

Exclusion Criteria:

* cardiac surgery without sternotomy
* peripheral neuropathy
* neurological disease
* psychiatric illness
* history of GI bleeding
* chronic pain (i.e. back pain, cancer, arthritis)
* serum creatinine \>150 μmol/l
* hepatic disease with elevated liver enzymes (SGPT and SGOT elevated to 1.5 times maximum normal value)
* allergic to study medication
* alcohol abuse
* abuse of narcotics or medication
* pregnancy
* participation in other clinical trials
* insufficient language skills
* In addition intensive care unit (ICU) stay for more than 24 hours was used as a pre-defined post randomization exclusion criteria, because prolonged ICU stay and ventilator treatment would interfere with study analgesic protocol.
C: Inclusion Criteria:

1. Age ≥40 years old.
2. Major non-cardiac surgical procedures scheduled to take ≥ two hours done under general anesthesia.
3. Written informed consent

Exclusion Criteria:

1. Recent intravenous or oral steroid therapy (within 30 days); inhaled steroids are permitted
2. Any contraindications to the proposed interventions
3. ASA Physical Status \> 4
4. Non English speaking patients
5. Procedures done under regional anesthesia
D: Inclusion Criteria:

* patients undergoing thyroid surgery

Exclusion Criteria:

* ASA physical class III or IV
* age \> 75 years
* pregnancy

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Pharmacy-based Interdisciplinary Program for Patients With Chronic Heart Failure (PHARM-CHF): A Randomized Controlled Trial
Brief Summary: The aim of the study is to investigate whether a continuous interdisciplinary intervention improves medication adherence (primary efficacy endpoint) and leads to a reduction of hospitalizations and mortality (primary safety endpoint) in elderly patients with chronic heart failure. The intervention, consisting of regular contacts with the local pharmacy and weekly dosing aids, aims to improve medication adherence and management.


Options:
A: Inclusion Criteria:

* type 2 diabetes
* stated concern about diabetes and diabetes treatment
* poor glycemic control
* over 21 years of age

Exclusion Criteria:

* blind, deaf, otherwise unable to use the telephone or visual resources
* pregnant
* currently enrolled in other REACH Detroit research study
* in hospice care
* current radiation or chemotherapy
B: Inclusion Criteria:

* Latinos older than 21
* Diagnosed with type 2 diabetes
* Referred to the "Amigos en Salud" program at Hartford Hospital
* Residents of Hartford

Exclusion Criteria:

* Advanced renal failure
* Advanced heart disease
* Diagnosis of major psychological disorder or mental condition
* Limb amputation(s) that prevent following study's exercise recommendations
* Any other health condition that prevents individual from consuming all their meals orally
C: Inclusion Criteria:

* Age: 60 years and older
* Chronic heart failure (CHF)
* Stable CHF medication including a diuretic
* Hospitalization for decompensated heart failure within past 12 months OR a value of ≥ 350 pg/mL for BNP or ≥ 1,400 pg/mL for NT-proBNP
* Written informed consent

Exclusion Criteria:

* Use of a weekly dosing aid
* Unwillingness or inability to visit a participating pharmacy once a week
* Planned cardiac surgery
* Life-expectancy \< 6 months
* Unwillingness or inability to comply with the study protocol (including drug abuse or alcohol dependency)
* Participation in other studies (currently or in the last 4 weeks)
D: Inclusion Criteria:

* Cost related medicine non-adherence during last 12 months

Exclusion Criteria:

* Family member living at same address of patient who is already enrolled in this trial
* Patient joined practice during last 6 months

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Brief Summary: The purpose of this study is to show biosimilarity of HX575 epoetin alfa with the US licensed reference product Epogen®/Procrit® when applied subcutaneously. This study is intended to generate data supporting that the efficacy and safety under treatment with HX575 and Epogen®/Procrit® are comparable.


Options:
A: Inclusion Criteria:

* Age \> = 18,
* End stage kidney disease and anemia
* Treatment with hemodialysis for renal replacement therapy
* no contraindications to erythropoietin stimulating agents (ESAs) or already treated with ESAs

Exclusion Criteria:

* Patients with Hb levels \> 10 g/dl without ESAs
B: Inclusion Criteria:

* Heart failure of at least 3 months duration and of New York Heart Association (NYHA) class II, III, or IV
* hemoglobin between 9.0 g/dL and 12.0 g/dL
* left ventricular ejection fraction equal to or less than 40%

Exclusion Criteria:

* Transferrin saturation (Tsat) \< 15%
* Blood pressure \> 160/100 mm Hg
* Heart failure primarily due to valvular heart disease or clinically significant valvular heart disease that might lead to surgical correction within 12 months of randomization
* Recipient of a major organ transplant or receiving renal replacement therapy
* Serum creatinine \> 3.0 mg/dL (\> 265 µmol/L)
C: Inclusion Criteria:

* adult patients \>=18 years of age;
* chronic renal anemia;
* on dialysis therapy for at least 12 weeks before screening;
* receiving IV epoetin for at least 8 weeks before screening.

Exclusion Criteria:

* women who are pregnant, breastfeeding or using unreliable birth control methods;
* administration of another investigational drug within 4 weeks before screening, or during the study period.
D: Inclusion Criteria:

* Patients with end stage renal disease (stage CKD 5d), receiving stable subcutaneous maintenance therapy with Epogen® or Procrit® at least once per week
* Mean hemoglobin level between 9.0 - 11.5 g/dL during the screening period
* Adequate iron substitution

Exclusion Criteria:

* Contraindications for Erythropoiesis Stimulating Agent (ESA) therapy
* History of Pure Red Cell Aplasia (PRCA), or anti-erythropoietin (EPO) antibodies
* Known Human Immunodeficiency Virus (HIV) or Hepatitis B infection
* Hepatitis C infection on an active treatment
* Symptomatic congestive heart failure (New York Heart Association \[NYHA\] class III and IV)
* Unstable angina pectoris, or cardiac infarction during the last 6 months prior to randomization
* Percutaneous coronary intervention, or coronary artery bypass grafting during the last 6 months prior to randomization
* History of malignancy of any organ system
* Systemic lupus erythematous
* Immunocompromized patients

Other In-/Exclusion criteria may apply

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Feasibility of an ED-initiated Online Asthma Management Program for Urban Teens (Puff City-ED)
Brief Summary: The objective of this study is to determine the feasibility of conducting a randomized controlled trial to evaluate the effectiveness of an online, Emergency Department-initiated asthma management intervention designed to reduce asthma-related morbidity among urban teenagers aged 13-19 years with uncontrolled asthma. The study will examine issues around recruitment, participant compliance with the study protocol, Internet access, and attrition. Investigators will first develop a protocol for recruiting 13-19 year old patients with acute asthma into an ED-initiated pilot trial of an online asthma management program, describing recruitment and refusal rates. Investigators will measure participant compliance with the pilot study protocol including 4 online sessions and a 6 month survey. Investigators will also measure compliance of the participants parents at baseline and a six month follow up. Investigators will then use pilot study results to describe the intervention effect on selected outcomes including ED visits, asthma control as measured by Asthma Control Questionnaire, functional limitations, quality of life, and behavior change.


Options:
A: Inclusion Criteria:

* Patients prescribed therapy equivalent to step 3 or higher on the Asthma Management Guidelines for at least 3 months
* At least one exacerbation in the previous year with systemic glucocorticoids
* Uncontrolled/Partially Controlled Asthma by GINA guidelines

Exclusion Criteria:

* Allergy to salmeterol/fluticasone
* Patients Controlled by GINA guidelines
B: Inclusion Criteria:

* Ages 13 - 18 years
* Prior asthma diagnosis
* Use of a prescribed asthma medication in the past 12 months
* Uncontrolled asthma, defined as (1) daytime symptoms 3+ days per week, (2) night awakenings 1+ nights per week, or (3) 2+ exacerbation events, i.e. 2+ steroid bursts; 2+ emergency department visits, or 1+ hospitalization for asthma.

Exclusion Criteria:

* Co-morbid diseases that affect lung functioning
C: Inclusion Criteria:

* 13-19 years of age
* Physician diagnosis of acute asthma at the Emergency Department visit
* Parent written informed consent
* Teen written informed assent

Exclusion Criteria:

* Inability to provide informed consent/assent
* No physician diagnosis of asthma
* Other co-morbidities that make it impossible for individual to participate.
D: Inclusion Criteria:

* Parents of children, aged 4-12 with moderate to severe asthma

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy of β-carotene Biofortified Maize in Improving Vitamin A Status and Reducing the Prevalence of Vitamin A Deficiency Among Children in Rural Zambia
Brief Summary: The purpose of this cluster-randomized trial is to examine whether daily consumption of β-carotene biofortified maize flour can reduce the prevalence of vitamin A deficiency and improve the vitamin A status and among 4-8 year old children in rural Zambia.


Options:
A: Inclusion Criteria:

1. Children aged 57-88 months at the time of initiation of the study
2. Children living in the locality defined by the study and not enrolled in school.
3. Consent from parent/guardian.

Exclusion Criteria:

1. Severely malnourished children (weight for age or height z-scores \<-3 standard deviations below the WHO growth reference standards)
2. Children found to be below 57 months and still holding an under five card or above 88 months at the time of initiation of the study or enrolled in school, based on verification of birth dates at screening
3. Children whose families plan to leave the study area before completion of the study
4. Consent not obtained from parent/guardian
5. Children suffering from diarrhea at the time of initiation of the study or with high fever, based on the report of symptoms by the parent/guardian
6. Children with severe anemia (Hb \<7.0 g/dL) as determined at the baseline blood draw.
B: Inclusion Criteria:

* Children 4-8 years of age
C: Inclusion Criteria:

4-6 months of age (stratified by HIV status) Infant able to take oral preparations Consent of parent/guardian HIV status obtained from mother and child

Exclusion Criteria:

Documented micronutrient supplementation other than vitamin A in the preceding month Less than 60% of mean weight for age by NCHS guidelines (micronutrient intervention obligatory according to WHO guidelines for management of severely malnourished children) Persistent diarrhea (\>=7 days) at the time of study enrollment Exclusive breastfeeding Infants in whom a second confirmatory HIV test cannot be obtained (when required) Co-enrollment of the infant in other clinical intervention trials e.g. antibiotic or vaccine trials
D: Inclusion Criteria:

* Infant receiving OPV and BCG within 48 hr of birth

Exclusion Criteria:

* Mother is less than 18 years of age
* Infant is part of a multiple birth
* Infant will likely not remain in the study area for the next 4 months
* Infant has a condition precluding vaccination
* Infant is unable to breastfeed or drink other fluids
* Birth weight is less than 1.5 kg

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomised Controlled Trail of Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy After Pancreaticoduodenectomy
Brief Summary: The purpose of this study is to determine whether duct-to-mucosa is better than invagination in pancreaticojejunostomy after pancreaticoduodenectomy. This single-centre, open, randomized controlled trail is conducted following ISGPF criteria for pancreatic fistula (PF). The duration of the study is supposed to start from Jan 5th 2012 and last to Dec 2014, until 100 or more cases are accessible. Patients diagnosed with pancreatic cancer, peri-ampullar carcinoma or other benign or malignant diseases which need to operate pancreaticoduodenectomy will be included. Main outcomes are pancreatic fistula rate, mortality, morbidity, reoperation and hospital stay. The investigators assumption that duct-to-mucosa is better than invagination.


Options:
A: Inclusion Criteria:

* Written Informed consent obtained；
* Both sexes between 18 and 80 years old；
* Patients scheduled to elective open pancreaticoduodenectomy.

Exclusion Criteria:

* Patients with ASA score \>=4;
* Patients who had a previous pancreatic operation;
* Patients with an immunodeficiency;
* Patients who underwent an emergency operation;
* Pregnant patients；
* Patients who was found that pancreaticoduodenectomy was not suitable。
B: Inclusion Criteria:

* Patients diagnosed with pancreatic cancer or other diseases which need pancreaticoduodenectomy and pancreaticojejunostomy
* 18 to 80 y/o
* Operation-tolerated
* Informed consent

Exclusion Criteria:

* History of gastrointestinal operation
* Pancreaticoduodenectomy is given up during operation
* Pancreatic duct is difficult to locate
* Patients require to exit from the study anytime
C: Inclusion Criteria:

-Consecutive patients who were treated by pancreaticoduodenectomy

Exclusion Criteria:

* Any patients with locally advanced periampullary tumour, metastases
* Patients received neoadjuvant chemoradiotherapy
* Patients underwent pancreaticogastrostomy (PG)
* Patients with advanced liver cirrhosis (Child B or C)
* Malnutrition
* Coagulopathy
D: Inclusion Criteria:

Patients from whom we obtained written informed consent of this study

Exclusion Criteria:

* Patients with severe ischemic cardiac disease
* Patients with severe liver damage
* Patients requiring oxygen administration due to interstitial pneumonia or pulmonary fibrosis
* Patients requiring dialysis treatment due to chronic renal failure
* Patients who are considered as inappropriate by attending physician

Answer: B